Insmed(US:INSM) Prnewswire·2026-01-28 12:00Core Insights - Insmed will present four abstracts on treprostinil palmitil inhalation powder (TPIP) at the PVRI 2026 congress, highlighting the Phase 3 PALM-PAH study design and Phase 2b study results in pulmonary arterial hypertension (PAH) [1] Group 1: Presentation Details - The presentations will include the Phase 3 PALM-PAH study design and an encore of the topline results from the Phase 2b study of TPIP in PAH [1] - A new Functional Respiratory Imaging analysis from the Phase 2b study and data on the pulmonary vasodilatory effect of TPIP in rat models will also be presented [1] - Specific presentation details include moderated poster discussions scheduled for January 30 and 31, 2026, covering various aspects of TPIP research [1] Group 2: About TPIP - TPIP is a dry powder formulation of treprostinil palmitil, designed for once-daily administration in patients with PAH and other pulmonary disorders [1] - The investigational drug has not yet received approval for any indication [1] - The Phase 2b study involved 102 adult participants across 44 sites, focusing on the efficacy, safety, and pharmacokinetics of TPIP [1] Group 3: About PAH - PAH is a serious and progressive disease characterized by high blood pressure in the pulmonary arteries, affecting approximately 35,000 patients in the U.S., 40,000 in the EU5, and 15,000 in Japan [1] - Common symptoms include shortness of breath, chest pain, dizziness, fatigue, and weakness, with untreated PAH often leading to debilitating and fatal outcomes [1] Group 4: About Insmed - Insmed is a global biopharmaceutical company focused on developing first- and best-in-class therapies for serious diseases [1] - The company has a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [2] - Insmed has been recognized as a top employer in the biopharmaceutical industry, emphasizing its commitment to employee satisfaction and innovation [2]